HOPE Therapeutics is training clinical staff ahead of deploying Zeta Surgical's robotic TMS system in Florida clinics, according to a September 11 company announcement from parent NRx Pharmaceuticals.
The practical advance Robotic coil positioning and head-movement tracking could support more consistent delivery. The announcement describes preparation for deployment, not a completed outcome study. Claimed precision and first-in-market status remain company assertions.
Regulatory context FDA record K261471 is dated July 9, 2026, not September. It covers the Zeta TMS Navigation System with an optional robotic coil-holder accessory for positioning compatible TMS coils using patient imaging. The clearance summary states that no clinical testing was required. It does not demonstrate superior depression outcomes.
Why it matters Clinicians can follow whether this workflow improves targeting consistency, staff workload and patient experience. Those practical measures should be evaluated separately from symptom response.
Sources and disclosure This is a company press release with commercial interests, not independent reporting. Regulatory details were checked against https://www.accessdata.fda.gov/cdrh_docs/pdf26/K261471.pdf. Prepared with AI assistance and source-checked September 12, 2026.